Fresenius SE & Co. KGaA (FSNUY) Stock
FSNUY has an Alpha Score of 44 out of 100 (weak), computed on Nov 4, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 1 trade in FSNUY since 2018: 0 purchases and 1 sale, most recently Greg Gianforte (sale, Dec 21, 2018). Its trailing P/E ratio is 17.2 and its net margin 6.6% (key statistics as of Oct 31, 2026).
What is FSNUY's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with weak momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Fresenius SE & Co. KGaA (FSNUY)?
Most recent: Greg Gianforte (sale, Dec 21, 2018); records start Dec 21, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Greg Gianforte R-MT · House | 2018-12-21 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 6, 2026.
See all FSNUY political trades →What are FSNUY's key statistics?
Key statistics as of Oct 31, 2026
How does FSNUY's valuation compare with the Healthcare sector?
| Metric | FSNUY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 17.2 | 29.7 | 114 |
| Net margin | 6.56% | 3.62% | 174 |
| Return on equity | 7.89% | 2.96% | 200 |
| Dividend yield (payers) | 3.29% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
FSNUY price chart
Powered by TradingViewWhat does Fresenius SE & Co. KGaA do?
Fresenius SE & Co. KGaA Sponsored ADR is a type of financial asset known as an American Depositary Receipt (ADR), representing shares in the German healthcare company, Fresenius SE & Co. KGaA. ADRs enable U.S. investors to access foreign companies' securities more easily. The primary purpose of this ADR is to facilitate investment in Fresenius SE & Co. KGaA by providing a means for its shares to be traded on U.S. stock exchanges. Fresenius operates in critical healthcare sectors such as dialysis, hospital management, and medical care products, impacting industries globally. With its diversified healthcare reach, the ADR plays a significant role in diversifying U.S. investors' portfolios internationally, while representing a key player in the global healthcare industry.